Evidence map›Paper›PMID 41567130›Full record

ArticleInternational journal of cardiology. Heart & vasculature2026

The efficacy of carvedilol in improving cardiac function and survival in patients with anthracycline-induced cardiotoxicity: a comprehensive systematic review and meta-analysis.

Sabahat Ul Ain Munir Abbasi, Riya Bhagwan, Aamna Rehman, Neha Malik, Sanya Ashraf Khaskheli, Najaf Ahmed Rajpar, Rayyan Nabi, Ayesha Amir Basra, Shehdev Meghwar, Raheel Ahmed and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sabahat Ul Ain Munir AbbasiAllama Iqbal Medical College, Lahore, Pakistan.
Riya BhagwanDow University of Health Sciences Karachi, Pakistan.
Aamna RehmanAllama Iqbal Medical College, Lahore, Pakistan.
Neha MalikAllama Iqbal Medical College, Lahore, Pakistan.
Sanya Ashraf KhaskheliLiaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
Najaf Ahmed RajparBilawal Medical College, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
Rayyan NabiIslamic International Medical College, Riphah International University, Pakistan.
Ayesha Amir BasraAkhtar Saeed Medical and Dental College, Lahore, Pakistan.
Shehdev MeghwarLiaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
Raheel AhmedNewcastle University, Freeman Hospital, Newcastle upon Tyne, Royal Brompton Hospital, London, UK.
Kalpana SinghHamad Medical Corporation, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anthracyclines (ANT) are widely used in chemotherapy, but their dose-dependent Cardiotoxicity limits long-term use. Carvedilol, a non-selective beta-blocker, has shown potential as a Cardioprotective agent for patients receiving ANT, though its overall effectiveness remains unclear. This systematic review and Methods: We performed a comprehensive search of major electronic databases through March 2025 for studies comparing carvedilol with placebo or no treatment in human subjects with ANT-Induced Cardiotoxicity. Primary outcomes included left ventricular ejection fraction (LVEF), left ventricular systolic dysfunction (LVSD), left ventricular systolic and diastolic diameters (LVsD, LVdD), and mortality. Secondary outcomes included echocardiographic and Doppler parameters. Random-effects models were used to calculate standard mean differences (SMDs) and risk ratios (RR) using RevMan 5.4. Results: A total of fourteen studies were included, thirteen in the Conclusion: Carvedilol appears to protect cardiac function in patients undergoing ANT therapy, though it does not significantly impact mortality. Further research is needed to determine optimal dosing, timing, and long-term survival benefits.

Indexed as

Anthracycline-induced cardiotoxicityBeta-blockersCarvedilolHeart failureLVEFMeta-analysisSystematic review

Identifiers

PMID41567130
PMCPMC12818984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.